Author: Editor

Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute gives an overview of her presentation, TP53 Mutation Carriers: Cancer Genetics in Survivorship Care, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute explains the significance of the shift from single gene testing to multiplex testing.This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania discusses the integration of information on genetic testing into clinical care. She states that with more discussion on genetic testing, more patients will be encouraged to receive testing. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania discusses the challenges that came with incorporating genetic testing into survivorship care. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania gives an overview of the key points clinicians should know when speaking with patients about genetic testing. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Grant Stewart, MBChB, FRCSEd (Urol), PhD, from the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses novel treatments for renal cell carcinoma (RCC) at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the efficacy of combination therapies which can enhance the efficacy of known drugs. Dr Stewart also describes challenges associated with having multiple combination approaches available, and speaks about new approaches to identify good drug combinations.

Gerald Mickisch, MD, from the Bremen Center of Operative Urology, Bremen, Germany, discusses how sequential therapy can be used in the treatment of castration-resistant prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Mickisch explains the efficacy of sequential therapy, and speaks about the order in which treatments are typically given to improve overall survival (OS).

Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses the ARASENS trial for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the three pillars of prostate cancer treatment: androgen deprivation therapy, androgen receptor suppression, and chemotherapy. Prof. Tombal introduces the hypothesis that combining these treatments will improve overall survival (OS), on which the Phase III ARASENS trial (NCT02799602) is based, and outlines the design of this study.

Anne Kiltie, MD, MRCP(UK), FRCR, from the University of Oxford, Oxford, UK, discusses bladder preservation in muscle invasive bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. She describes bladder sparing approaches using a combination of chemotherapy and radiotherapy before carrying out surgery to remove the bladder, and how these vary between different countries. Prof. Kiltie highlights her interest in the treatment of elderly patients, for whom not all therapy options may be available.

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses what uro-oncologists should know about new drugs in 2017 at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Roupret highlights the importance of clinical implications, and explains why clinicians should be informed about what is most important in the management of the disease and treatment side effects.

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses optimization of contemporary bladder cancer care at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights that bladder cancer has been treated with the same tools for over 30 years, and speaks about new therapies which are now available. Prof. Roupret also points out why a multidisciplinary team approach is needed for bladder cancer management.

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK, discusses the potential of intraprostatic PRX302 injection for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages of imaging technologies to visualize the tumor, and speaks about how this allows localized treatment to be carried out and what this means for the patient. Prof. Emberton describes different approaches for targeting the tumor, including energy sources and pharmaceutical approaches, and outlines how the effects of the bacterial toxin PRX302 can be limited to the prostate. He speaks…

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Philip D. Bonomi discusses new approaches to the treatment of cachexia. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Nurse Beth Eaby-Sandy discusses how to communicate with families regarding expectations for treatment outcomes. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses the role of zoledronic acid, denosumab, and other strategies in the treatment of bone metastases. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Corey J. Langer discusses the targeting of angiogenesis in non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Ranee Mehra discusses the management of T790-negative EGFR-mutated non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Tracey L. Evans discusses the management of T790-positive EGFR-mutated non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses how, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR-positive non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Barbara A. Burtness discusses current and future strategies for esophageal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vassiliki Papadimitrakopoulou discusses the changing face of first- and second-line therapy for squamous cell carcinoma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this discussion, the co-chairs of the European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes 2017 highlight the key points presented during the meeting, with the aim of sharing updates that will help you enhance your clinical practice. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=EMDS © 2017 Imedex, LLC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes the effect and consequences of when ER-p53 tumors attach to mutant p53. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes his other study that focuses on the use of tamoxifen therapy for triple negative breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics discusses how to customize therapy based on the stratification of p53. He further explains with the stratification of p53 status, clinicians can now come up with new strategies for treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics gives an overview of his abstract, Novel effect of tamoxifen therapy: disruption of ER-p53 interaction leading to altered gene expression profile in human breast tumors, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center gives an overview of one of her presentations, The Effects of Tumor Microenvironment on Metastasis and Therapy Resistance , which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center discusses the treatment trends for 2017 in oncology at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center gives an overview of one of her presentations, Taming the Tumor Microenvironment in Pancreatic Cancer, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center explains the importance in understanding the language of tumors for cancer research and treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center discusses the research on tumor microenvironment and its impact on cancer research and overall standard of care. She argues the research data helps predict potential tumors and can potentially develop novel pathways and novel treatments to help lower risk in patients. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center explains how the genotype of a tumor affects overall tumor behavior and its response to therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses the treatment trends for 2017 which include combination therapy and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses whether or not there is a correlation between biomarkers, specifically PD-L1 and tumor mutation burden, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses the impact of Checkmate-026 on current cancer research, stating the data encourages clinicians to move and assess the biomarkers in all ongoing trials. She also argues that the biomarker can help predict which patients will benefit from early therapeutic treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital gives an overview of her presentation, Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate -026, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University discusses the treatment trends for 2017 include immunotherapy and checkpoint inhibitors, but according to him, treatment should focus more on early detection and prevention of cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Athena Matakidou of the Cambridge Cancer Centre discusses Preclinical models of renal cancer at the 12th European International Kidney Cancer Symposium 2017.

Henry Withers of Roswell Park Cancer Institute, Department of Genetics gives an overview of his presentation, Characterization of an off-target RNAi genomic screen hit identifies GPRC6A as a novel suppressor of metastatic chemotaxis and invasiveness, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Henry Withers of Roswell Park Cancer Institute, Department of Genetics discusses how the data can predict which patients are at risk for metastatic disease and his hopes for a potential biomarker that can be used to identify patients with aggressive prostate cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains where to place immunotherapy in overall treatment plans for cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of presentations that were discussed at the AACR 2017 annual meeting. She describes the use of immune checkpoint blocking drugs in four different types of cancers: breast cancer, melanoma, merkel cell carcinoma, and lung cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the use of ipilimumab and nivolumab in advanced melanoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the importance of checkpoint inhibitors, specifically avelumab, in merkel cell cancers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of presentations at the AACR 2017 annual meeting, specifically data results from a clinical trial on triple negative breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of the AACR presentations, which focused greatly on immunotherapy, biomarkers, and combinations. She further explains the impact of immunotherapy on all types of cancer treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute discusses the use of liquid biopsies of microRNAs as a follow-up method for patients with breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute describes the lack of immunotherapy in treatment for breast cancer, stating the biggest challenge in breast cancer research is figuring out a way to utilize immunotherapy in treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Novel microRNA signature score to predict bone metastasis and prognosis of breast cancer, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.